Literature DB >> 10326194

Comparison of continuation rates for hormonal contraception among adolescents.

A Zibners1, B A Cromer, J Hayes.   

Abstract

BACKGROUND: Inadequate contraception is common among sexually active female adolescents, resulting in a high incidence of unwanted pregnancy. The authors were interested in comparing continuation rates for the different forms of hormonal contraception in this age group.
METHODS: A retrospective chart review. The setting was an urban clinic in a large Midwestern city. Participants were 64% black, 34% white, and the average age was 15.5 years (+/- 1.6 SD), with implant users significantly older than oral contraceptive pill (OCP) users (P < .05). Interventions were self-selection to depo-medroxyprogesterone acetate (Depo-Provera; DMPA), levonorgestrel implants (Norplant), or oral contraceptive pills (OCPs). Previous pregnancy was significantly more prevalent in implant and DMPA users than in OCP users (P < .001). Over 4 years of follow-up, continuation rates were significantly higher for implant users than for the other hormonal groups (P < .001). At 1 year, continuation rates were as follows: 82% implants, 45% DMPA, and 12% OCPs. Combining these rates with those of the subsample who switched without interruption to another hormonal method, "continued protection" rates were much higher after 1 year: 96% implants, 83% DMPA, and 49% OCPs. Calculations of contraceptive "restarts," i.e., hormonal method use in those who discontinued and then restarted after a gap of time, also increased to the prevalence of contraceptive protection.
CONCLUSION: Continuation rates for levonorgestrel implants were significantly higher than those for DMPA and OCPs, the latter group having the lowest continuation rates. Factoring in switches and restarts to other hormonal methods further boosted the prevalence rates of contraceptive use in the adolescent population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10326194     DOI: 10.1016/s1083-3188(00)86633-4

Source DB:  PubMed          Journal:  J Pediatr Adolesc Gynecol        ISSN: 1083-3188            Impact factor:   1.814


  8 in total

1.  Oral contraceptive use and depression among adolescents.

Authors:  Sarah McKetta; Katherine M Keyes
Journal:  Ann Epidemiol       Date:  2018-10-13       Impact factor: 3.797

2.  Efficacy, user acceptability, tolerability, and cycle control of a combined contraceptive vaginal ring: the Indian perspective.

Authors:  Anita Soni; Seeru Garg; Rani Bangar
Journal:  J Obstet Gynaecol India       Date:  2013-05-01

3.  Continuation of reversible contraception in teenagers and young women.

Authors:  Jessica R Rosenstock; Jeffrey F Peipert; Tessa Madden; Qiuhong Zhao; Gina M Secura
Journal:  Obstet Gynecol       Date:  2012-12       Impact factor: 7.661

4.  Provider counseling to young women seeking family planning services.

Authors:  Alexandra M Minnis; Sue Napierala Mavedzenge; Ellen Luecke; Christine Dehlendorf
Journal:  Perspect Sex Reprod Health       Date:  2014-05-01

5.  Attitudes and beliefs about the intrauterine device among teenagers and young women.

Authors:  Kendra L Fleming; Abby Sokoloff; Tina R Raine
Journal:  Contraception       Date:  2010-04-13       Impact factor: 3.375

6.  Influence of depressed mood and psychological stress symptoms on perceived oral contraceptive side effects and discontinuation in young minority women.

Authors:  Kelli Stidham Hall; Katharine O'Connell White; Vaughn I Rickert; Nancy Reame; Carolyn Westhoff
Journal:  Contraception       Date:  2012-06-04       Impact factor: 3.375

7.  Contraception for adolescents with lupus.

Authors:  Melissa S Tesher; Amy Whitaker; Melissa Gilliam; Linda Wagner-Weiner; Karen B Onel
Journal:  Pediatr Rheumatol Online J       Date:  2010-03-31       Impact factor: 3.054

8.  Adolescent and young women's experience with the vaginal ring and oral contraceptive pills.

Authors:  Felicia H Stewart; Beth A Brown; Tina R Raine; Tracy A Weitz; Cynthia C Harper
Journal:  J Pediatr Adolesc Gynecol       Date:  2007-12       Impact factor: 1.814

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.